Sonitor Introduces SonitorBLU™ and SonitorMOBILE™
17.4.2023 19:35:00 EEST | Business Wire | Press release
Sonitor® Technologies today announced expansion of its market leading Sense™ platform with SonitorBLU, a proprietary Bluetooth Low Energy (BLE) solution for use cases when zonal accuracy is required, and SonitorMOBILE, a location visibility platform for positioning smart devices, combining Sonitor’s ultrasound technology with BLE to provide best-in-class accuracy, effectively turning a smart phone into an RTLS tag. The company made the announcement at the HIMSS Global Health Conference where it is exhibiting from April 18-20.
Sonitor’s new portfolio offers a tiered approach to the challenges faced by healthcare providers. These range from simple asset tracking to more demanding applications that require speed and accuracy such as patient flow and clinical workflow, as well as the critical need to ensure staff safety. As with Sense, these new products offer advanced analytics for workflow insights, and appropriate staffing assignments that help increase hospital capacity and improve patient and staff satisfaction.
“Sonitor is excited to invite healthcare providers, technology partners and all HIMSS attendees to our booth where we will be showcasing the SonitorBLU, Sonitor Sense and SonitorMOBILE suite of products,” said Matt Crane, Chief Commercial Officer, North America/CEO, Sonitor Inc. “In addition, we have recently expanded our team of clinical and technology experts to customize Sonitor’s solutions to meet customers’ strategic objectives and budgets.”
With SonitorBLU, hospitals have an easy-to-install platform to address use cases such as asset tracking when near real-time data flow is sufficient. With no cabling, installation is simple and fast, and the system can be up and reporting locations in less than a day. SonitorMOBILE, combines Sonitor’s patented ultrasound technology, SonitorULE™, and BLE to provide centimeter level accuracy with refresh rates of 1-2 seconds, to “move at the speed of a nurse™,” for highly demanding use cases.
About Sonitor
Sonitor Technologies AS is the leading provider of accurate, affordable, and easy to use Real Time Locating Systems (RTLS) with wearables for staff safety and workforce enablement. The first and only company to commercialize low energy ultrasound as the primary locating technology with proven 99.9% location accuracy, SonitorULE™, is more affordable than traditional RTLS platforms using radio (RF or RFID) or infrared (IR) technologies. Based on its proven record for uptime performance in clinical settings, Sonitor is the only RTLS company to offer a 5-year warranty as standard on its infrastructure technology. The company received a high ranking in the 2023 Best in KLAS RTLS report, second only to the winner, Sonitor partner Securitas Healthcare. Sonitor also earned certification as a “Great Place to Work®” in 2022 and was recognized as among the top companies poised for growth based on innovation and customer alignment in Frost & Sullivan’s Radar™ Industry Report for Indoor Positioning Systems (IPS). To learn more visit www.sonitor.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230417005644/en/
Contact information
Dan Conley
Beacon Communications dconley@beaconpr.com
+1-312-593-8461
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom